WO2001083693A3 - Composes ayant une affinite pour le recepteur 2 du facteur de croissance de l'endothelium vasculaire (vegfr-2) et utilisations associees - Google Patents

Composes ayant une affinite pour le recepteur 2 du facteur de croissance de l'endothelium vasculaire (vegfr-2) et utilisations associees Download PDF

Info

Publication number
WO2001083693A3
WO2001083693A3 PCT/US2001/013598 US0113598W WO0183693A3 WO 2001083693 A3 WO2001083693 A3 WO 2001083693A3 US 0113598 W US0113598 W US 0113598W WO 0183693 A3 WO0183693 A3 WO 0183693A3
Authority
WO
WIPO (PCT)
Prior art keywords
vegfr
compounds
affinity
growth factor
vascular endothelial
Prior art date
Application number
PCT/US2001/013598
Other languages
English (en)
Other versions
WO2001083693A8 (fr
WO2001083693A2 (fr
Inventor
Peter Joseph Schatz
Min-Jia Chen
Sunila Piplani
Cecilia A Mozsgai
Palani Balu
Original Assignee
Glaxo Group Ltd
Peter Joseph Schatz
Min-Jia Chen
Sunila Piplani
Cecilia A Mozsgai
Palani Balu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd, Peter Joseph Schatz, Min-Jia Chen, Sunila Piplani, Cecilia A Mozsgai, Palani Balu filed Critical Glaxo Group Ltd
Priority to AU2001259195A priority Critical patent/AU2001259195A1/en
Publication of WO2001083693A2 publication Critical patent/WO2001083693A2/fr
Publication of WO2001083693A8 publication Critical patent/WO2001083693A8/fr
Publication of WO2001083693A3 publication Critical patent/WO2001083693A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Nouveaux composés qui se lient à VEGFR-2. Ces nouveaux composés possèdent une chaîne peptidique d'une longueur appoximative de 8 à 40 acides aminés qui se lie à VEGFR-2, ou bien sont des dimères de telles chaînes peptidiques. Lesdits composés sont utiles en tant que sondes pour le criblage d'affinité et en tant qu'agents d'imagerie de l'angiogenèse. En outre, ces composés qui sont des antagonistes de VEGFR-2 sont utiles pour traiter, entre autres, des maladies dont le cancer, la rétinopathie, l'arthrite rhumatoïde. Des compositions pharmaceutiques et des méthodes d'utilisation desdites compositions sont également décrites.
PCT/US2001/013598 2000-04-28 2001-04-27 Composes ayant une affinite pour le recepteur 2 du facteur de croissance de l'endothelium vasculaire (vegfr-2) et utilisations associees WO2001083693A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001259195A AU2001259195A1 (en) 2000-04-28 2001-04-27 Compounds having affinity for the vascular endothelial growth factor receptor-2 (vegfr-2) and associated uses

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56147000A 2000-04-28 2000-04-28
US09/561,470 2000-04-28

Publications (3)

Publication Number Publication Date
WO2001083693A2 WO2001083693A2 (fr) 2001-11-08
WO2001083693A8 WO2001083693A8 (fr) 2002-01-31
WO2001083693A3 true WO2001083693A3 (fr) 2003-04-10

Family

ID=24242110

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/013598 WO2001083693A2 (fr) 2000-04-28 2001-04-27 Composes ayant une affinite pour le recepteur 2 du facteur de croissance de l'endothelium vasculaire (vegfr-2) et utilisations associees

Country Status (2)

Country Link
AU (1) AU2001259195A1 (fr)
WO (1) WO2001083693A2 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2286843A3 (fr) 2000-06-02 2011-08-03 Bracco Suisse SA Composés pour le ciblage de cellules endothéliales
US8263739B2 (en) 2000-06-02 2012-09-11 Bracco Suisse Sa Compounds for targeting endothelial cells, compositions containing the same and methods for their use
US7261876B2 (en) 2002-03-01 2007-08-28 Bracco International Bv Multivalent constructs for therapeutic and diagnostic applications
US8623822B2 (en) 2002-03-01 2014-01-07 Bracco Suisse Sa KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
EP1587944A4 (fr) 2002-03-01 2007-03-21 Dyax Corp Peptides de liaison kdr et vegf/kdr et leur utilisation a des fins diagnostiques et therapeutiques
US7794693B2 (en) 2002-03-01 2010-09-14 Bracco International B.V. Targeting vector-phospholipid conjugates
NO20026285D0 (no) * 2002-12-30 2002-12-30 Amersham Health As Nye peptider
DK2284180T3 (en) 2003-03-03 2015-12-21 Dyax Corp Uses of peptides that specifically bind to the HGF receptor (cMET)
EP1812030A4 (fr) * 2004-10-14 2009-01-14 Sopherion Therapeutics Inc Peptides anti-angiogeniques et procedes d'utilisation de ceux-ci
SI2197900T1 (sl) * 2007-08-24 2012-11-30 Julius Maximilians Uni Wurzburg Mutantni dvojno ciklizirani receptorski peptidi ki inhibirajo protitelesa beta adrenoceptorja
DE102010026061A1 (de) * 2010-06-30 2012-01-05 Siemens Aktiengesellschaft 11C-markiertes Peptid zur Detektion eines Tumors, der einen Her2/neu-Rezeptor exprimiert
DE102010026064A1 (de) * 2010-06-30 2012-01-05 Siemens Aktiengesellschaft 11C-markiertes Peptid zur Detektion eines krankhaften Gewebes
DE102010026063A1 (de) * 2010-06-30 2012-01-05 Siemens Aktiengesellschaft 11C-markiertes Peptid zur Detektion eines krankhaften Gewebes
EP2541193A1 (fr) 2011-06-27 2013-01-02 Hexagon Technology Center GmbH Procédé de mesure d'éloignement interférométrique pour la mesure de surfaces et un tel appareil de mesure

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BINETRUY-TOURNAIRE, R. ET AL.: "Identification of a peptide blocking vascular endothelial growth factor (VEGF)-mediated angiogenesis", THE EMBO JOURNAL, vol. 19, no. 7, 3 April 2000 (2000-04-03), pages 1525 - 1533, XP002179245 *
COOPER, M.E. ET AL.: "Increased renal expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in experimental diabetes", DIABETES, vol. 48, November 1999 (1999-11-01), pages 2229 - 2239, XP002951265 *
DATABASE GENBANK [online] 20 April 2000 (2000-04-20), JORDON, R. ET AL.: "Arabidopsis thaliana protein T14D3.70", XP002951210, accession no. STN Database accession no. (T47453) *
STACKER, S.A. ET AL.: "A mutant form of vascular endothelial growth factor (VEGF) that lacks VEGF receptor-2 activation retains the ability to induce vascular permeability", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 247, no. 49, 3 December 1999 (1999-12-03), pages 34884 - 34892, XP002951264 *

Also Published As

Publication number Publication date
AU2001259195A1 (en) 2001-11-12
WO2001083693A8 (fr) 2002-01-31
WO2001083693A2 (fr) 2001-11-08

Similar Documents

Publication Publication Date Title
WO2001083693A8 (fr) Composes ayant une affinite pour le recepteur 2 du facteur de croissance de l'endothelium vasculaire (vegfr-2) et utilisations associees
AU3651802A (en) Recombinant anti-cd30 antibodies and uses thereof
ATE425181T1 (de) Therapeutische zusammensetzungen aus antikorper und antisens nukleinsäuren gegen serrate
EE05309B1 (et) β-Amloidpeptiidi „ratundvad humaniseeritud antikehad, meetod nende valmistamiseks, nende kasutamine ja farmatseutiline kompositsioon
UA29494C2 (uk) Гуманізовані антитіла, способи їх продукування, спосіб лікування хвороби крона, спосіб лікування розсіяного склерозу, фармацевтична композиція
JP2008519589A (ja) 造血を促進する分子
EA200000331A1 (ru) Фармацевтические композиции, содержащие белок плазмы
BG112197A (bg) Антитела срещу рецептора за инсулин-подобния растежен фактор i
CY1107051T1 (el) Αντι-διηθητικα και αντι-αγγειογενετικα θραυσματα ουροκινασης και η χρηση τους
EA200200755A1 (ru) Опосредованная рецептором nogo блокада роста аксонов
WO2001036640A3 (fr) Gene humain fgf-21 et produits d'expression genique
CA2267661A1 (fr) Variants de facteur de croissance de cellules endotheliales vasculaires possedant des proprietes antagonistes
EP2353611A3 (fr) Conjugués de médicaments et leur utilisation pour traiter le cancer, maladie auto-immune ou maladie infectieuse
WO2005001038A3 (fr) Anticorps anti-cd30 de recombinaison et leurs utilisations
IL152659A (en) Liquid pharmaceutical compositions comprising a pegylated human erythropoietin protein and a multiple charged inorganic anion, in a pharmaceutically acceptable buffer
WO2002026776A3 (fr) Composés à base de peptides
EP1242115A4 (fr) Immunite chimiquement programmable
IL108322A0 (en) Metal complexes and metal complex conjugates of endotheline derivatives, methods for the preparation thereof and diagnostic compositions containing the same
DE60319135D1 (de) Peptide, die die heparinbindungsdomäne von vegf und vegfr-2 binden
WO2001042284A3 (fr) Proteine de liaison
WO2004058803A3 (fr) Nouveaux peptides
WO2002007676A3 (fr) Composés à affinité pour le récepteur du facteur de stimulation des colonies de granulocytes (g-csfr)
KR970015597A (ko) 비오틴 유도체
RU96118231A (ru) Биотиновые производные, способ их получения, фармацевтические композиции и способ их получения
Tu Neurotoxins from snake venom

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: C1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: PAT. BUL. 45/2001 UNDER (81) ADD "CO"

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP